BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26414667)

  • 1. Tet oncogene family member 2 gene alterations in childhood acute myeloid leukemia.
    Li MJ; Yang YL; Lee NC; Jou ST; Lu MY; Chang HH; Lin KH; Peng CT; Lin DT
    J Formos Med Assoc; 2016 Sep; 115(9):801-6. PubMed ID: 26414667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
    Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
    J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
    Wang R; Gao X; Yu L
    BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
    Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
    Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Analysis of clinical significance and prognostic impact of TET2 single nucleotide polymorphism I1762V in patients with acute myeloid leukemia].
    Li YW; Guo Z; Wang LL; Zhou L; Lyu XD; Song YP
    Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):241-246. PubMed ID: 35405783
    [No Abstract]   [Full Text] [Related]  

  • 6. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.
    Liu WJ; Tan XH; Luo XP; Guo BP; Wei ZJ; Ke Q; He S; Cen H
    Leuk Lymphoma; 2014 Dec; 55(12):2691-8. PubMed ID: 24524305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TET2 missense variants in human neoplasia. A proposal of structural and functional classification.
    Bussaglia E; Antón R; Nomdedéu JF; Fuentes-Prior P
    Mol Genet Genomic Med; 2019 Jul; 7(7):e00772. PubMed ID: 31187595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
    Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
    J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
    Aslanyan MG; Kroeze LI; Langemeijer SM; Koorenhof-Scheele TN; Massop M; van Hoogen P; Stevens-Linders E; van de Locht LT; Tönnissen E; van der Heijden A; da Silva-Coelho P; Cilloni D; Saglio G; Marie JP; Tang R; Labar B; Amadori S; Muus P; Willemze R; Marijt EW; de Witte T; van der Reijden BA; Suciu S; Jansen JH
    Ann Hematol; 2014 Aug; 93(8):1401-12. PubMed ID: 24994606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Landscape of TET2 mutations in acute myeloid leukemia.
    Weissmann S; Alpermann T; Grossmann V; Kowarsch A; Nadarajah N; Eder C; Dicker F; Fasan A; Haferlach C; Haferlach T; Kern W; Schnittger S; Kohlmann A
    Leukemia; 2012 May; 26(5):934-42. PubMed ID: 22116554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of TET2 SNP rs2454206 with improved survival in children with acute myeloid leukemia featuring intermediate-risk cytogenetics.
    Wang X; Chen X; Yang Z; Dou H; Lu L; Bi J; Zou L; Yu J; Bao L
    Genes Chromosomes Cancer; 2018 Aug; 57(8):379-386. PubMed ID: 29664232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.
    Yamazaki J; Taby R; Jelinek J; Raynal NJ; Cesaroni M; Pierce SA; Kornblau SM; Bueso-Ramos CE; Ravandi F; Kantarjian HM; Issa JP
    J Natl Cancer Inst; 2015 Nov; 108(2):. PubMed ID: 26568194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression and prognosis analysis of
    Zhang T; Zhao Y; Zhao Y; Zhou J
    Aging (Albany NY); 2020 Mar; 12(6):5031-5047. PubMed ID: 32209730
    [No Abstract]   [Full Text] [Related]  

  • 14. TET2 mutations in cytogenetically normal acute myeloid leukemia: clinical implications and evolutionary patterns.
    Damm F; Markus B; Thol F; Morgan M; Göhring G; Schlegelberger B; Krauter J; Heuser M; Bernard OA; Ganser A
    Genes Chromosomes Cancer; 2014 Oct; 53(10):824-32. PubMed ID: 24898826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of the Effect of TET2 Mutation and SNP on Clinical Characteristics and Prognosis of AML Patients].
    Li L; An LC; Chu XX; Liu XQ; Wang L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):453-459. PubMed ID: 32319378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Next-generation sequencing with a myeloid gene panel in core-binding factor AML showed KIT activation loop and TET2 mutations predictive of outcome.
    Cher CY; Leung GM; Au CH; Chan TL; Ma ES; Sim JP; Gill H; Lie AK; Liang R; Wong KF; Siu LL; Tsui CS; So CC; Wong HW; Yip SF; Lee HK; Liu HS; Lau JS; Luk TH; Lau CK; Lin SY; Kwong YL; Leung AY
    Blood Cancer J; 2016 Jul; 6(7):e442. PubMed ID: 27391574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical Significance of Truncated Mutant ΔJBP of TET2 Gene in Patients with Acute Myeloid Leukemia].
    Yang YC; Xia T; Luo M; Guo WZ; Zhang LL; Chen XH; Xu ZF; Wang HW; Tan YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Aug; 29(4):1011-1018. PubMed ID: 34362476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
    Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
    Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TET2 mutations contribute to adverse prognosis in acute myeloid leukemia (AML): results from a comprehensive analysis of 502 AML cases and the Beat AML public database.
    Pan X; Chang Y; Ruan G; Zhou S; Jiang H; Jiang Q; Huang X; Zhao XS
    Clin Exp Med; 2024 Feb; 24(1):35. PubMed ID: 38349460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
    Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
    Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.